New publication: Real-world study prospectively shows prognostic and predictive accuracy We are excited to share the latest prospective findings from a study entitled “Long-term prospective outcome data using EndoPredict as risk stratification an... Read More
NICE in UK recommends EndoPredict® for tailored treatment of lymph node positive early breast cancer New guidance from the National Institute for Health and Care Excellence (NICE)1 The National Institute for Health and Care Excellence (NICE) in the UK has i... Read More
Phase III validation of EndoPredict® confirms prognostic power Prognostic value of EndoPredict® test in patients with hormone receptor positive, human epidermal growth factor receptor 2-negative primary breast cancer scre... Read More
Updated ESMO Guidelines 2024 Level of Evidence (LoE) 1A for all gene expression assays in early ER+ HER2- breast cancer We are pleased to share the latest insights from the ESMO Clinica... Read More